Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery and characterization of an anti-<i>Neisseria gonorrhoeae</i> NGO_1985 monoclonal antibody and cognate antigen.

Frontiers in microbiology·2026
Same author

Human antibodies as emerging drugs for antimicrobial resistance.

Trends in immunology·2026
Same author

B-cell DNA methylation signature in response to hepatitis B virus vaccination in females and males.

Frontiers in immunology·2026
Same author

DNA methylation signatures of treatment response in medication-overuse headache.

The journal of headache and pain·2026
Same author

Epimutations in migraine and in medication overuse headache: a longitudinal study after acute medication withdrawal.

The journal of headache and pain·2026
Same author

Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Related Experiment Video

Updated: Jun 10, 2026

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis.

Claudia Sala1, Neeraj Dhar, Ruben C Hartkoorn

  • 1Global Health Institute, Institute, Ecole Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland.

Antimicrobial Agents and Chemotherapy
|August 4, 2010
PubMed
Summary

Developing new tuberculosis (TB) drugs is challenging due to dormant Mycobacterium tuberculosis cells. A novel streptomycin-dependent strain model effectively screens drugs against nonreplicating TB bacteria, identifying promising candidates for dormant TB therapy.

More Related Videos

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria
09:57

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria

Published on: December 14, 2016

Related Experiment Videos

Last Updated: Jun 10, 2026

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria
09:57

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria

Published on: December 14, 2016

Area of Science:

  • Microbiology
  • Drug Discovery
  • Tuberculosis Research

Background:

  • Dormant Mycobacterium tuberculosis (TB) cells are phenotypically resistant to standard TB therapies, posing a significant challenge to treatment efficacy.
  • Developing new drugs that target nonreplicating or dormant TB bacilli is crucial for eradicating the disease.

Purpose of the Study:

  • To establish a simple and effective model for screening anti-TB drugs against nonreplicating Mycobacterium tuberculosis.
  • To evaluate the efficacy of existing and experimental TB drugs against dormant M. tuberculosis using a streptomycin-dependent strain.

Main Methods:

  • Utilized the streptomycin (STR)-dependent 18b strain of M. tuberculosis, which replicates with STR and survives without multiplication upon STR withdrawal.
  • Assessed drug susceptibility of nonreplicating 18b cells to isoniazid (INH), rifampin (RIF), TMC207, PA-824, meropenem (MER), benzothiazinone (BTZ), and moxifloxacin (MOXI).
  • Adapted the resazurin reduction assay for high-throughput screening of dormant M. tuberculosis inhibitors.

Main Results:

  • Drug susceptibility varied significantly in nonreplicating versus replicating M. tuberculosis 18b cells; cell wall inhibitors (INH, BTZ) were less effective, while RIF and PA-824 showed increased efficacy.
  • Drug potency rankings against nonreplicating M. tuberculosis in vitro correlated with in vivo efficacy in a mouse model of chronic TB infection.
  • The resazurin reduction assay demonstrated that dormant M. tuberculosis 18b retains metabolic activity and is suitable for high-throughput drug screening.

Conclusions:

  • The streptomycin-dependent 18b strain of M. tuberculosis provides a valuable model for evaluating drug efficacy against dormant bacilli.
  • This model facilitates the identification of novel drug candidates effective against nonreplicating M. tuberculosis, addressing a critical gap in TB therapy.
  • High-throughput screening using this model holds promise for discovering new inhibitors to combat dormant tuberculosis infections.